BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33408094)

  • 1. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
    You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance.
    Liu J; Curtin J; You D; Hillerman S; Li-Wang B; Eraslan R; Xie J; Swanson J; Ho CP; Oppenheimer S; Warrack BM; McNaney CA; Nelson DM; Blum J; Kim T; Fereshteh M; Reily M; Shipkova P; Murtaza A; Sanjuan M; Hunt JT; Salter-Cid L
    PLoS One; 2019; 14(3):e0212670. PubMed ID: 30913212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.
    Hernandez S; Qing J; Thibodeau RH; Du X; Park S; Lee HM; Xu M; Oh S; Navarro A; Roose-Girma M; Newman RJ; Warming S; Nannini M; Sampath D; Kim JM; Grogan JL; Mellman I
    Cell Rep; 2018 Oct; 25(1):80-94. PubMed ID: 30282040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPK1 as a novel target for cancer immunotherapy.
    Sawasdikosol S; Zha R; Yang B; Burakoff S
    Immunol Res; 2012 Dec; 54(1-3):262-5. PubMed ID: 22477524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
    Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Taniguchi T; Umezaki Y; Nakazawa Y; Uesugi S; Mori K; Horiuchi T; Obuchi W; Minami M; Shimada T; Wada C; Yoshida T; Higuchi S
    Eur J Pharmacol; 2023 Dec; 961():176184. PubMed ID: 37944847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity.
    Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Higuchi S
    Biochem Biophys Res Commun; 2024 Jun; 715():149995. PubMed ID: 38685185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High HPK1
    Zhang J; Ren Z; Hu Y; Shang S; Wang R; Ma J; Zhang Z; Wu M; Wang F; Yu J; Chen D
    Int Immunopharmacol; 2024 Jan; 127():111363. PubMed ID: 38101218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.
    Wang Y; Zhang K; Georgiev P; Wells S; Xu H; Lacey BM; Xu Z; Laskey J; Mcleod R; Methot JL; Bittinger M; Pasternak A; Ranganath S
    PLoS One; 2020; 15(12):e0243145. PubMed ID: 33270695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
    Wang MS; Wang ZZ; Li ZL; Gong Y; Duan CX; Cheng QH; Huang W; Yang GF
    J Med Chem; 2023 Jan; 66(1):611-626. PubMed ID: 36542759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1.
    Zhou L; Ye X; Wang K; Shen H; Wang T; Zhang X; Jiang S; Xiao Y; Zhang K
    Bioorg Chem; 2023 Sep; 138():106682. PubMed ID: 37339563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of small-molecule inhibitors targeting HPK1.
    Zhou L; Wang T; Zhang K; Zhang X; Jiang S
    Eur J Med Chem; 2022 Dec; 244():114819. PubMed ID: 36209628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.
    Malchow S; Korepanova A; Panchal SC; McClure RA; Longenecker KL; Qiu W; Zhao H; Cheng M; Guo J; Klinge KL; Trusk P; Pratt SD; Li T; Kurnick MD; Duan L; Shoemaker AR; Gopalakrishnan SM; Warder SE; Shotwell JB; Lai A; Sun C; Osuma AT; Pappano WN
    ACS Chem Biol; 2022 Mar; 17(3):556-566. PubMed ID: 35188729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).
    Linney ID; Kaila N
    Expert Opin Ther Pat; 2021 Oct; 31(10):893-910. PubMed ID: 33956554
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.
    Si J; Shi X; Sun S; Zou B; Li Y; An D; Lin X; Gao Y; Long F; Pang B; Liu X; Liu T; Chi W; Chen L; Dimitrov DS; Sun Y; Du X; Yin W; Gao G; Min J; Wei L; Liao X
    Cancer Cell; 2020 Oct; 38(4):551-566.e11. PubMed ID: 32860752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors.
    Zhang J; Li Y; Tang H; Zhou Q; Tong L; Ding J; Xie H; Xiong B; Liu T
    Bioorg Chem; 2023 Nov; 140():106811. PubMed ID: 37659145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPK1 Influences Regulatory T Cell Functions.
    Sawasdikosol S; Zha R; Fisher TS; Alzabin S; Burakoff SJ
    Immunohorizons; 2020 Jul; 4(7):382-391. PubMed ID: 32631900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.